Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.
After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.
Structure Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, Yoon JunMarch 3, 2026, 22,305 Ordinary Shares were disposed of through shares withheld by the company to cover income tax obligations tied to the vesting of a restricted share unit award at $20.99 per share, a tax-withholding disposition rather than an open-market sale. Following this, Yoon Jun directly held 1,297,571 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. The company notes that its Ordinary Shares may be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.'s Chief Development Officer Ashley Hall reported several routine share movements. On March 3, 2026, Hall disposed of 4,836 Ordinary Shares at $20.99 per share to cover income taxes on a vesting restricted share unit award, leaving 107,481 Ordinary Shares directly owned.
Earlier, Hall acquired 225 American Depositary Shares (ADSs) on May 20, 2025 and 237 ADSs on November 20, 2025 through the company’s Employee Share Purchase Plan. Each ADS represents three Ordinary Shares and is convertible into Ordinary Shares at any time with no expiration date.
Structure Therapeutics Inc. CEO Raymond C. Stevens reported mixed share movements related primarily to tax withholding and existing holdings. On March 3, 2026, 53,454 Ordinary Shares were disposed of at $20.99 per share, withheld by the company to satisfy income tax obligations tied to a restricted share unit vesting.
After this tax-withholding disposition, Stevens directly held 1,141,376 Ordinary Shares. Indirectly, 1,554,586 Ordinary Shares and 12,000 American Depositary Shares (ADSs) are held by the Stevens 2001 Revocable Trust, where Raymond Stevens and Vivian Urena-Stevens act as co-trustees.
The filing also notes an earlier non-cash acquisition on November 20, 2025, when Stevens was granted 824 ADSs at $0.0000 per ADS under the company’s Employee Share Purchase Plan, bringing that direct ADS position to 1,824 ADSs. Each ADS represents three Ordinary Shares and has no expiration date.
Structure Therapeutics is a clinical-stage biopharma company using structure-based design and computational chemistry to create oral small molecules that target GPCRs for chronic diseases, with a major focus on obesity and metabolic disorders.
The lead candidate, aleniglipron, an oral GLP‑1 receptor agonist, delivered placebo‑adjusted mean weight loss of 11.3% at 120 mg in the 36‑week Phase 2b ACCESS study and 15.3% at 240 mg in the exploratory ACCESS II study, with class‑consistent gastrointestinal side effects and no reported drug‑induced liver injury or QTc issues. Multiple Phase 2 and extension studies support moving into Phase 3 obesity trials in the second half of 2026.
The company is also advancing oral amylin receptor agonists ACCG‑2671 and ACCG‑3535 into Phase 1, plus early GIP and glucagon receptor programs, while retaining a broad GPCR pipeline. In December 2025, a subsidiary licensed certain non‑core GLP‑1 patents to Genentech and Roche for a $100 million upfront payment and future low single‑digit royalties.
Structure Therapeutics Inc. reported its fourth quarter and full-year 2025 results and provided a pipeline update focused on obesity treatments. Positive Phase 2 aleniglipron data showed significant weight loss across all doses, reaching up to 15.3% at 36 weeks, supporting advancement into Phase 3, which is expected to start in the second half of 2026.
The company reported cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, which it expects to fund operations and key clinical milestones through the end of 2028. Fourth quarter 2025 R&D expenses were $68.7 million and full-year R&D totaled $225.3 million, reflecting expanded clinical activity. Other license income of $100.0 million and $10.2 million of gains on sale of non-financial assets contributed to fourth quarter 2025 net income of $33.0 million, compared to a net loss of $36.5 million a year earlier. For full-year 2025, the company recorded a net loss of $141.2 million, compared to a net loss of $122.5 million in 2024.
Structure Therapeutics Inc. received an amended Schedule 13G showing that a group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert collectively report beneficial ownership of 10,437,066 ordinary shares. This equals about 4.9% of the company’s 211,917,574 shares outstanding as of December 11, 2025.
The stake is primarily held through three BVF funds, with BVF owning 5,583,855 shares, BVF II holding 4,053,954 shares and Biotechnology Value Trading Fund OS LP holding 643,536 shares, largely via American Depositary Shares. The filers certify the position is passive and not for influencing control.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 12,335,346 ordinary shares of Structure Therapeutics Inc., equal to 5.95% of the class as of December 31, 2025.
The ownership is calculated using 207,417,574 ordinary shares outstanding as of December 10, 2025, based on the issuer’s prospectus. The position includes 4,111,782 American Depositary Shares, each representing three ordinary shares. The filers certify the holdings are not for the purpose of changing or influencing control of the company.
Structure Therapeutics Inc. received a Schedule 13G/A showing that Wellington Management Group LLP and related entities beneficially own 21,365,952 shares of common stock, representing 10.08% of the company’s outstanding shares as of December 31, 2025.
Wellington reports shared voting power over 19,433,943 shares and shared dispositive power over 21,365,952 shares, with no sole voting or dispositive power. The shares are held of record by Wellington investment-advisory clients, and no single client is said to hold more than five percent of the class.
Wellington certifies the holdings are kept in the ordinary course of business and are not intended to change or influence control of Structure Therapeutics, indicating a passive institutional ownership position.
Structure Therapeutics Inc received an amended Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 31,112,634 shares of its common stock, representing 15.0% of the class as of December 31, 2025.
FMR LLC has sole voting and dispositive power over these shares, while Abigail P. Johnson has sole dispositive power. The filers certify that the securities were acquired and are held on a passive basis, not to change or influence control of Structure Therapeutics.